Vaccine produces long-lasting anti-tumor response in patients with melanoma

January 21, 2021

BOSTON - Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard report in a new study.

The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient's tumor cells. The researchers found that, nearly four years after vaccination, the patients' immune system cells were active not only against tumor cells with those distinctive proteins, but also spread to other proteins found in those patients' tumor cells.

"These findings demonstrate that a personal neoantigen vaccine can stimulate a durable immune response in patients with melanoma," says study co-leader Catherine J. Wu, MD, of Dana-Farber, Brigham and Women's Hospital (BWH), and the Broad Institute. "We found evidence that the initial, targeted immune response has broadened over the years to provide patients with continued protection from the disease."

The study involved eight patients who had undergone surgery for advanced melanoma but were considered at high risk of recurrence. In a Phase 1 clinical trial, they were treated with NeoVax a median of 18 weeks after surgery. The vaccine is made from bits of proteins, called epitopes, that poke from the cell surface and serve as signals to the immune system. The epitopes in NeoVax come from neoantigens - abnormal proteins on tumor cells that warn that a cell is cancerous and should be destroyed. Because neoantigens are found only on tumor cells, they trigger an immune response that spares normal cells from attack.

To make NeoVax, the sequence of DNA in a patient's tumor is scanned in order to identify the key epitopes within the tumor cell neoantigens. The epitopes serve as targets for T cells, which lead the immune system's attack on cancer. When a patient is treated with NeoVax, the epitopes draw an immune system response against any melanoma cell that displays them.

In the new study, researchers found that a median of four years after NeoVax treatment, all eight patients were alive, with six showing no signs of active disease. When they analyzed the patients' T cells - the immune system cells spurred to action by the vaccine - they found evidence that the cells not only "remembered" their initial target epitopes but had expanded their repertoire to recognize other melanoma-related epitopes as well.

Two of the patients, whose cancer had spread to their lungs, also received an immune checkpoint inhibitor, a drug that loosens some of the restraints on the immune response to cancer. In those two patients, the researchers detected signs that T cells had made their way into the tumor tissue, where they could be most lethal to melanoma cells.

"We found evidence of everything we look for in a strong, sustained immune response," says Patrick A. Ott, MD, PhD, of Dana-Farber, Brigham and Women's Hospital (BWH), and the Broad Institute, who co-led the study with Wu. "T cells continued to specifically target melanoma cells and retained a memory of the epitopes they initially responded to. The T cells were activated to kill tumor cells and, critically, had diversified to target melanoma epitopes not included in the original vaccine.

"The long-term persistence and expansion of the melanoma-targeting T cells is a strong indication that personal neoantigen peptide vaccines can help control metastatic tumors, particularly when combined with immune checkpoint inhibition."
The lead authors of the study are Zhuting Hu, PhD, and Donna E. Leet, of Dana-Farber. The co-authors are Rosa L. Allesoe, of the University of Copenhagen; Giacomo Oliveira, PhD, Adrienne M. Luoma, PhD, Teddy Huang, PhD, Robert Redd, MS, Jing Sun, PhD, Anita Giobbie-Hurder, MS, Wandi Zhang, Zoe Ciantra, Oriol Olive, Keerthi Shetty, PhD, MBA, Jason Pyrdol, Mohamed Uduman, PhD, Patrick C. Lee, Donna Neuberg, ScD, Kenneth J. Livak, PhD, and Kai Wucherpfennig, MD, PhD, of Dana-Farber; Shuqiang Li, PhD, Juliet Forman, Sachet A. Shukla, PhD, Edward F. Fritsch, PhD, and Derin B. Keskin, PhD, of Dana-Farber and the Broad Institute; Pavan Bachireddy, MD, of Dana-Farber, the Broad Institute, and BWH; Satyen Gohil, MD, PhD, of Dana-Farber, the Broad Institute and University College, London; J. Bryan Iorgulescu, MD, Elizabeth I. Buchbinder, MD, and Scott Rodig, MD, PhD, of Dana-Farber and BWH; Jinyan Liu, MD, PhD, and Lauren Peter, of Beth Israel Deaconess Medical Center; Rebecca Holden, PhD, of Massachusetts Institute of Technology (MIT); Bradley L. Pentelute, PhD, of MIT and the Broad Institute; Siranush Sarkizova, PhD, and Liudmilla Elagina, of the Broad Institute; Nir Hacohen, PhD, of the Broad Institute and Massachusetts General Hospital; Charles H. Yoon, MD, PhD, of BWH; Lars Rønn Olsen, of Technical University of Denmark and Copenhagen University Hospital; and Dan H. Barouch, MD, PhD, of Beth Israel Deaconess Medical Center and the Ragon Institute of MGH, MIT, and Harvard.

Financial support for the study was provided by the Blavatnik Family Foundation, the National Institutes of Health (grants NCI-1R01CA155010; NCI- U24CA22433; NCI-SPORE-2P50CA101942-11A1; NCI-R50 RCA211482A; NCI-R50 CA251956; NCI-R01 CA229261; NCI P01 CA163222; NCI- R01 CA238039; and NCI-5T32HL007627); the Melanoma Research Alliance; the Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund; the Faircloth Family Research Fund; the Bender Family Research Fund, a Dana-Farber Cancer Institute Cancer Immunotherapy Research fellowship and 5 T32 CA 207021-3; the Damon Runyon Cancer Research Foundation; the Be The Match Foundation; the American Society of Hematology; an NSF Graduate Research Fellowship; a Kay Kendall Leukaemia Fund Fellowship, the G. Harold and Leila Y. Mathers Foundation; and the Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center, the Howard Hughes Medical Institute Medical Research Fellows Program and the Novo Nordisk Foundation (grant agreement NNF14CC0001).

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber/Brigham and Women's Cancer Center and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 10 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

Dana-Farber Cancer Institute

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to